Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics Inc. has announced a peer-reviewed study published in the Journal of Translational Medicine showcasing the potential of its product AccuTOX® as an effective anti-cancer molecule. The study highlights AccuTOX®’s ability to induce cell death in various cancer lines and enhance immune system detection of cancer, with promising preclinical results showing therapeutic superiority over its parent molecule without apparent toxicity.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
